Occam Places CSO of ADC Biotech MBrace Therapeutics
In March 2024, Occam recruited Steve Alley, PhD, as Chief Scientific Officer for MBrace Therapeutics, a Venrock, TPG, and Cowen investment.
Alley joins MBrace Therapeutics after serving as the Executive Director of Translational Sciences at Seagen. During his tenure at Seagen, Alley played a crucial role in the company's rapid growth by assuming various leadership positions in research and development. Alley led the bioanalysis and DMPK groups, contributed to developing Seagen's ADC technology platform, and led the cross-functional team that discovered the Seagen Sugar Engineered Antibody technology platform.
MBrace was founded in 2020 by CEO Isan Chen, M.D.,formerly CMO of Mirati Therapeutics; Renata Pasqualini, Ph.D.; and Wadih Arap, M.D./Ph.D. MBrace is a clinical-stage biopharmaceutical company developing innovative ADC cancer therapeutics utilizing the SPARTA technology pioneered by its founders.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.